For many years, blood-based biomarkers for Alzheimer's disease seemed unattainable, but
recent results have shown that they could become a reality. Convincing data generated with …

Breakthroughs in molecular medicine have positioned the amyloid-β (Aβ) pathway at the
center of Alzheimer's disease (AD) pathophysiology. While the detailed molecular …

The extracellular buildup of amyloid beta (Aβ) plaques in the brain is a hallmark of
Alzheimer's disease (AD). Detection of Aβ pathology is essential for AD diagnosis and for …

Importance Plasma phosphorylated tau at threonine 181 (p-tau181) has been proposed as
an easily accessible biomarker for the detection of Alzheimer disease (AD) pathology, but its …

Background Blood-based biomarkers for Alzheimer's disease (AD) might facilitate
identification of participants for clinical trials targeting amyloid beta (Abeta) accumulation …

Introduction Blood‐based biomarkers of amyloid pathology and neurodegeneration are
entering clinical use. It is critical to understand what factors affect the levels of these markers …

Tau phosphorylated at threonine 181 (p-tau181) measured in blood plasma has recently
been proposed as an accessible, scalable, and highly specific biomarker for Alzheimer's …

Alzheimer's disease (AD) is the number one neurovegetative disease, but its treatment
options are relatively few and ineffective. In efforts to discover new strategies for AD therapy …

Introduction We studied usefulness of combining blood amyloid beta (Aβ) 42/Aβ40,
phosphorylated tau (p‐tau) 217, and neurofilament light (NfL) to detect abnormal brain Aβ …

Staging the severity of Alzheimer's disease pathology using biomarkers is useful for
therapeutic trials and clinical prognosis. Disease staging with amyloid and tau PET has face …